SPONSOR
Genentech, Inc.
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 1, Phase 2
Conditions studied: Systemic Lupus ErythematosusRelapsed or Refractory Multiple MyelomaModerate to Severe Ulcerative Colitis
NCT06984341 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
NCT05927571 Phase 1
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
NCT06693908 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis